CVS Caremark’s GLP-1 Shake-Up: Big Changes for Denver Patients

Good news if you have commercial insurance: CVS Caremark — one of the largest pharmacy benefit managers in the country — just made it significantly easier to get GLP-1 weight loss medications. Two major changes landed this week, and both matter for people managing obesity in the Denver area.

What’s Changed

First, Foundayo gets the green light. CVS Caremark is removing the “new-to-market block” on Foundayo (orforglipron) starting June 1, 2026. That means patients with commercial CVS Caremark insurance can now access Lilly’s once-daily oral GLP-1 pill without the prior authorization hurdle that typically comes with a brand-new drug launch. Foundayo is the only GLP-1 pill you can take any time of day, with or without food — no fasting required, no needles.
Second, Zepbound is coming back. CVS Caremark will add Zepbound (tirzepatide) back to its preferred formulary as an additional option starting October 1, 2026. This is notable because CVS had previously excluded Zepbound, steering patients toward Wegovy. Now both drugs will have comparable commercial coverage for the first time.

Why This Matters for You

CVS Caremark covers a huge chunk of commercially insured Americans. These changes mean that if you have insurance through a large employer that uses CVS Caremark as its PBM, you’re more likely to have a covered option that actually fits your life — whether that’s an oral medication you take on your own schedule or an injectable with the strongest weight loss data currently available.

This also matters because we’re in the middle of a broader GLP-1 access expansion. Combined with the Medicare GLP-1 Bridge launching July 1, 2026 — which brings $50/month GLP-1 coverage to Medicare Part D beneficiaries — the insurance landscape is shifting fast. What was inaccessible six months ago may now be within reach.

Clinical Takeaway

These formulary changes reflect a bigger reality: GLP-1s are becoming standard obesity care, not niche specialty drugs. That’s good news for patients who’ve been stuck in the “prior authorization loop” or paying full cash price.

If you have CVS Caremark commercial insurance and have been unable to get Zepbound or Foundayo covered, it’s worth calling your pharmacy or your doctor’s office to revisit the conversation — the formulary landscape changed as of today.

And if you’re on Medicare, mark July 1, 2026 on your calendar. That’s when the Medicare GLP-1 Bridge kicks in.

The bottom line: More GLP-1 options are becoming more affordable for more patients. If you’ve been waiting for the right time to explore these medications, the insurance environment just got significantly friendlier.
Ready to find out which GLP-1 option might work for you? The team at Clinical Nutrition Center in Greenwood Village can help you navigate the options and handle the prior authorization process.